Quantum BioPharma Set to Shine at Global Growth and Investment Conference

WTS Capital
September 25, 2024

Quantum BioPharma Ltd. is gearing up to present at the upcoming Global Growth and Investment Conference, hosted by ArcStone Securities and Investments and Kingswood US. The event, taking place on September 26, 2024, in Toronto, will showcase over 30 public and private companies, providing a platform for networking and investment opportunities.

Key Takeaways

  • Event Date: September 26, 2024
  • Location: Sheraton Hotel, Downtown Toronto, ON
  • Speaker: Jason Sawyer, Head of Finance and Mergers and Acquisitions
  • Presentation Time: 2:45 PM - 2:55 PM, followed by a Q&A session
  • Focus: Growth potential of Quantum BioPharma and investor engagement

About Quantum BioPharma

Quantum BioPharma, formerly known as FSD Pharma Inc., is a biopharmaceutical company focused on developing innovative solutions for neurodegenerative and metabolic disorders. The company is particularly known for its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation, a key factor in multiple sclerosis.

The company has made significant strides in its research and development efforts, with Lucid-MS currently in preclinical stages. Additionally, Quantum BioPharma has a strategic partnership with Celly Nutrition Corp., which allows it to retain a significant stake and receive royalty payments from its product, unbuzzd™.

The Conference Overview

The Global Growth and Investment Conference is designed to connect emerging companies with potential investors. With 47 sponsors and a diverse range of companies participating, the event aims to foster meaningful discussions and collaborations.

  • Participants: Over 30 companies from various sectors
  • Sponsors: 47 sponsors, enhancing networking opportunities
  • Objective: To create value for both management and investors

Jason Sawyer's Role

As the Head of Finance and Mergers and Acquisitions, Jason Sawyer will play a pivotal role at the conference. His presentation will focus on the growth trajectory of Quantum BioPharma, highlighting the company’s innovative approaches and future plans.

  • Panel Discussions: Engaging with key investors and industry leaders
  • Networking Opportunities: Building relationships with potential partners and stakeholders

Future Prospects

Quantum BioPharma is not only focused on its current projects but is also looking ahead to future opportunities. The company retains a large tax loss carry forward of approximately C$130 million, which could be beneficial in offsetting future tax obligations. Furthermore, it maintains 100% rights to develop similar products for pharmaceutical and medical uses.

Conclusion

The Global Growth and Investment Conference presents a significant opportunity for Quantum BioPharma to showcase its innovations and connect with investors. With a strong focus on growth and strategic partnerships, the company is poised to make a lasting impact in the biopharmaceutical industry.

Sources

Share

Related Articles

Alamos Gold Establishes New Research Chair to Combat Gastrointestinal Cancers

Alamos Gold has established a new research chair to enhance the detection and treatment of gastrointestinal cancers, contributing $2 million to The Princess Margaret Cancer Foundation.

Sep 20, 2024

Is Elite Pharmaceuticals Ready for a Breakout? New Product Launches Could Fuel Growth

Elite Pharma sets sights on market growth with key product rollouts ahead.

Aug 24, 2024

Plurilock Security Shares Are Up 90% In The Past Week: Here’s Why

Plurilock shares rise following patent filing and executive appointment.

Aug 19, 2024

Disclaimer

Welcome To Walk The Street

We're just a bunch of guys mixing up market news with our own brand of banter, giving you the lowdown on stocks with a twist at Walk The Street Capital.